These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17014581)

  • 1. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.
    Castera L; Constant A; Henry C; Champbenoit P; Bernard PH; De Ledinghen V; Demotes-Mainard J; Couzigou P
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1223-30. PubMed ID: 17014581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
    Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
    J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
    Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
    Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
    Yang Z; Zhuang L; Yang L; Liu C; Lu Y; Xu Q; Chen X; Chen L
    Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):440-50. PubMed ID: 24176812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
    Abergel A; Hezode C; Leroy V; Barange K; Bronowicki JP; Tran A; Alric L; Castera L; Bernard PH; Henquell C; Lafeuille H; Ughetto S; Darcha C; Chevallier M; Martineau N; Dubost S; Randl K; Dhumeaux D; Bommelaer G; Bonny C;
    J Viral Hepat; 2006 Dec; 13(12):811-20. PubMed ID: 17109680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
    Lodato F; Azzaroli F; Brillanti S; Colecchia A; Tamé MR; Montagnani M; Muratori R; Giovanelli S; Feletti V; Bacchi Reggiani ML; Roda E; Mazzella G
    J Viral Hepat; 2005 Sep; 12(5):536-42. PubMed ID: 16108771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
    Yu ML; Dai CY; Lin ZY; Lee LP; Hou NJ; Hsieh MY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Feb; 26(1):73-81. PubMed ID: 16420512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
    Bruno S; Cammà C; Di Marco V; Rumi M; Vinci M; Camozzi M; Rebucci C; Di Bona D; Colombo M; Craxì A; Mondelli MU; Pinzello G
    J Hepatol; 2004 Sep; 41(3):474-81. PubMed ID: 15336451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
    Sánchez-Tapias JM; Crespo J; Diago M; Pérez R; Romero-Gómez M; Muñoz-Sánchez M
    Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):579-84. PubMed ID: 12616704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
    Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
    Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.